Trial 0C-13-7


A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Type: Treatment
Phase: Phase I
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Anayansi Miloud, D.M., Xiomara Menendez, R.N., Khatchik Karakozian, D.M., Molly Oswald, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.